The 100-day plan is a core tool of private equity value creation: stabilize operations, strengthen management and launch growth initiatives. In medtech, a plan built only around cost, integration and growth can overlook the regulatory, clinical and manufacturing work that decides whether the acquisition thesis holds. Compliance gaps, clinical evidence gaps and manufacturing constraints that surface after close are harder and more expensive to address once integration decisions are locked in.
This article sets out what a medtech-specific 100-day plan prioritizes and how pre-acquisition diligence should feed it.
The Gap Between the Standard Playbook and Medtech
Standard 100-day plans assume a relatively stable operating environment: integrate financial systems, pull cost levers, realign sales and marketing. That works for many industrial, software and services businesses. Medical devices add constraints. The device is already on the market, customers expect uninterrupted supply, and regulatory obligations continue through the transition. A missed quality or reporting obligation is not just a missed internal target; it can lead to inspection findings, warning letters and recalls. And a growth plan that assumes new indications depends on regulatory and clinical work that takes time.
When the first months go to cost reduction and financial integration, regulatory and clinical work can be under-resourced exactly when it matters most, and problems surface only after integration decisions are made.
Days 1-30: Regulatory and Quality Review
In medtech, the first month is the time for a structured regulatory and quality review. Focus areas include: open FDA actions, such as warning letters and Form FDA 483 observations from recent inspections, which can be checked against FDA's warning letter pages and its inspection data dashboard; the state of the quality system against FDA's Quality Management System Regulation (21 CFR Part 820), which has incorporated ISO 13485:2016 since February 2, 2026; design, manufacturing or labeling changes that may have needed a new submission or supplement; and whether complaints and adverse events are handled and reported, including medical device reports due within 30 calendar days under 21 CFR 803.50.
The later this review happens, the longer any gap has had to compound. A component that was never formally validated but is in production use becomes a remediation project that competes for capital and management attention.
Signs a 100-Day Plan Is Missing Critical Milestones
Signs that regulatory and clinical work is being deprioritized: (1) no dedicated regulatory resource allocated to the integration; (2) quality system improvements treated as “Phase 2” initiatives rather than early priorities; (3) clinical evidence gaps identified in diligence with no specific timelines; (4) manufacturing validation requirements missing from the operating plan; (5) no explicit go/no-go decision point for pursuing new indications or geographic expansion.
Days 30-60: Clinical Evidence Gaps
By the second month, the integration team should know whether the clinical evidence supports the growth thesis. Growth plans often assume new patient populations, indications or geographies, while the evidence may come from controlled trials or limited real-world use. An evidence gap analysis asks what payers would need to see before covering the new use, what clinicians in the target specialty would want before adopting it, and whether efficacy or safety questions call for additional clinical work.
Days 60-100: Manufacturing Reality Check
If the growth plan calls for several times current production, someone needs to validate that it is achievable: can the contract manufacturer support the volumes, are there single-source supplier constraints, and is the design ready for higher-volume production? A device made reliably at 500 units a month may struggle at 2,500 because manual assembly steps become bottlenecks, supplier capacity tightens or quality variation grows. Scale-up pilots and capacity validation belong in this window; if the assessment waits until month four or five, the company may already be committed to growth plans it cannot meet. See our manufacturing due diligence questions.
How Pre-Acquisition Diligence Feeds the Plan
The strongest 100-day plans start from the diligence findings. Regulatory compliance risk found in diligence becomes a Days 1-30 priority; clinical evidence gaps become the Days 30-60 work stream; manufacturing scaling concerns set the focus for Days 60-100. When diligence findings are filed away and the operating plan starts from a generic agenda, issues emerge after they are already embedded in financial plans and operating assumptions.
Vantage's reports for private equity are meant to be used this way: a $20,000 Diligence Report or a $25,000 M&A Report, reviewed by a physician and a biomedical engineer, with the M&A Report adding integration risk and reference-contact review, gives the operating team cited findings to prioritize.
A Common Sequence
A familiar pattern: the acquisition closes on schedule and the first month goes to financial integration and cost reduction. In the second month a regulatory question arrives, such as a response owed on a Form 483 observation or a question about whether a change needed a new submission, and the team discovers that its regulatory function is small and stretched, and that growth assumptions depend on regulatory clarity it does not yet have. A structured regulatory and clinical review in the first 30 days, informed by pre-acquisition diligence, is how to find these issues before they spread into broader integration problems.
The Bottom Line
A medtech 100-day plan works best when its sequence reflects the business: regulatory and quality review first, clinical evidence validation next, then a manufacturing reality check, with cost reduction and efficiency work built on a confirmed regulatory and clinical thesis. Plans that follow the standard playbook risk discovering those issues months later, at greater cost.
References
- FDA. "Warning Letters." fda.gov
- FDA Data Dashboard. "Inspections." datadashboard.fda.gov
- FDA. "FDA Form 483 Frequently Asked Questions." fda.gov
- FDA. "Quality Management System Regulation (QMSR)." fda.gov
- 21 CFR 803.50, "Individual adverse event reports; manufacturers." law.cornell.edu
Need a Custom Analysis?
Vantage full reports assemble the public record on a company, cite factual claims to their sources, and are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME. Start with a free 20-minute call.